FDA Approves Another Over-the-Counter Naloxone Nasal Spray for Opioid Overdose Reversal
By
Shannon Firth
Summary
The FDA has approved another over-the-counter naloxone nasal spray (Rextovy, 4-mg) for emergency opioid overdose reversal, joining other nonprescription products. The first OTC naloxone was approved in 2023. The agency notes that increased availability of nonprescription naloxone nasal sprays could help reduce costs and improve access to this life-saving medication.
Source
bskyFDA Approves Another Over-the-Counter Naloxone Nasal Spray for Opioid Overdose Reversalmedpagetoday.comKey quotes
· 3 pulledThe FDA approved another opioid overdose reversal product for over-the-counter (OTC) use, the agency announced on Tuesday.
The 4-mg intranasal naloxone hydrochloride (Rextovy) nasal spray joins other similar nonprescription products indicated for the emergency treatment of an opioid overdose.
Immediate access to naloxone...
You might also wanna read
FDA Approves Noroxone Nasal Spray That Reverses Narcan's Effects
The FDA has approved a new nasal spray called noroxone that reverses the effects of Narcan, with the stated goal of increasing fatalities am
The Onion·6mo ago
FDA Approves First Non-Opioid Pain Reliever: Journavx by Vertex Pharmaceuticals
The FDA approved Vertex Pharmaceuticals's Journavx (suzetrigine) in January 2025, marking the first non-opioid pain reliever.
worksinprogress.news·1y ago
WHO updates clinical guidelines for opioid dependence treatment and overdose prevention
WHO has updated its guidelines on opioid dependence treatment and opioid overdose management. The update reaffirms strong recommendations fo
who.int·2d ago
Modified Fentanyl Molecule Reduces Respiratory Risk While Maintaining Pain Relief
Researchers have developed a modified version of fentanyl that reduces the dangerous respiratory depression side effect while maintaining fu
Symptom-Based Dosing May Improve Discharge Readiness for Infants with Neonatal Opioid Withdrawal Syndrome
This study assessed whether a symptom-based dosing strategy for opioid treatment reduces time to medical readiness for discharge compared wi
ja.ma·4d ago
Unapproved weight-loss drug retatrutide widely available online, creating challenges for clinicians
Retatrutide, an investigational triple hormone receptor agonist not yet approved by the FDA for any indication, is being widely sold online
mdsc.pe·1d ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.